Billy Caldwell reaches 21 after years of treatment for severe epilepsy

The case shows how continuity of supply can matter for people whose symptoms are controlled by a prescribed medicine: the article links a temporary 2023 supply problem with a brief return of seizures. It also distinguishes a change in legal and regulatory access from routine availability in public healthcare. Charlotte Caldwell says many patients still depend on costly and inconsistent private prescriptions because NHS prescribing is limited, meaning the policy change has not necessarily translated into equal practical access for families managing severe epilepsy.

In 2018, the UK government granted Billy Caldwell’s family a licence for cannabis oil after his medicine was confiscated and he was hospitalised. The Guardian reports that, weeks later, the government accepted evidence of therapeutic benefit for some conditions and relaxed laws governing access to cannabis-derived medicine. That change enabled cannabis-based treatments to be prescribed in the UK, but the article reports that prescriptions through the NHS remain severely restricted. Charlotte Caldwell has founded an advocacy group, Transparent Responsible Adult-Use Controlled Data (TRACD), to press for change. The available account therefore places Billy’s current health alongside an unresolved access question rather than presenting legal reform as universal availability.

The report is centred on one family’s experience and on statements from Billy Caldwell’s mother; it does not provide clinical records, details of dosage, a diagnosis beyond severe epilepsy, or comparative evidence showing that CBD would have the same effect for other patients. It says that UK prescriptions require clinical-trial evidence and that NHS access is restricted, but does not quantify prescription rates, eligibility criteria, costs, or regional differences. Billy’s seizure-free period is also reported by his mother, and the article notes one recurrence during a supply glitch in 2023.